Corporate Research Report: Envisagenics
Company Overview
Name:
Envisagenics
Mission of the Company:
Envisagenics leverages Artificial Intelligence (AI) and Machine Learning (ML) to unlock the therapeutic potential of RNA.
Founding:
- Year Founded: 2014
- Founding Origin: Spinout of Cold Spring Harbor Laboratory (CSHL)
Key People:
- Maria Luisa Pineda, PhD
- Role: Co-Founder & CEO
- Background: Awarded endowment from the Goizueta Foundation, NIH fellowship recipient, Doctorate from Cold Spring Harbor Laboratory, investment experience in tech and life-sciences startup companies.
- Martin Akerman, PhD
- Role: Co-Founder & CTO
- Background: Inventor of SpliceCore®, trained in RNA splicing, PhD in Bioinformatics from Technion.
- Board Members:
- Michael Grissinger, MBA
- Executive BD, Johnson & Johnson
- Grant Verstandig
- Co-Founder, Red Cell Partners; Founder, Rally Health
- Scientific and Business Advisory Board:
- Adrian Krainer, PhD
- Professor & Program Chair, Cold Spring Harbor Laboratory
- Michael Q Zhang, PhD
- Professor & Director, Center for Systems Biology, University of Texas at Dallas; Guest Professor, Tsinghua University
- Omar I. Abdel-Wahab, MD
- Hematologic Oncologist, Memorial Sloan Kettering Center for Hematologic Malignancies
- Sudhir Agrawal, D.Phil, FRSC
- Founding Scientist, Idera Pharmaceuticals; Visiting Professor, University of Massachusetts Medical School
Headquarters:
30-02 48th Ave, Suites 140 and 150, Long Island City, New York NY 11101
Number of Employees:
No information is available
Revenue:
No information is available
Known For:
Envisagenics is known for its SpliceCore® software platform that accelerates the discovery of splicing-derived drug targets for RNA therapeutics.
Products
SpliceCore® Platform
- Description: An AI/ML-powered platform that transforms RNA sequencing data to discover novel drug targets.
- Key Features:
- Identifies new targets for RNA therapeutics.
- Validates splicing events and drug targets with high accuracy.
- Provides a large search space for target discovery using an exon-centric approach.
- Excels in experimental validation and disease-specific splicing events.
SpliceIO™
- Description: The immunotherapeutic branch of SpliceCore®.
- Key Features:
- Identifies tumor-specific neoepitopes.
- Enables development of antibody-based modalities for cancer treatment.
Recent Developments
New Products Launched:
- SpliceCore® Platform: Continues to evolve, integrating novel features for better RNA therapeutic discoveries.
- SpliceIO™: Developed as a specialized module for identifying tumor-specific biomarkers and neoepitopes.
New Features:
- Identification and validation of splice-switching oligonucleotides (SSOs) for targeted therapy in several cancer types.
- Enhanced cloud architecture for scalable processing of massive RNA-seq data.
Strategic Collaborations:
- Cancer Research Horizons and Queen Mary University of London (Dec 13, 2022): Collaboration to explore RNA splicing in hematopoietic cancers.
- Bristol Myers Squibb (BMS) (Nov 29, 2022): Partnership for accelerated discovery and development of oncology therapeutic candidates.
- Lung Cancer Initiative at Johnson & Johnson: Ongoing research program announced earlier.
- Collaboration with Biogen (May 13, 2021): Advanced research on RNA splicing.
- Collaboration with Cancer Research Horizons: To leverage SpliceCore® for expanded drug target discovery and development.
Notable Achievements:
- Publication in Molecular Systems Biology (April 25, 2024): Validation of the SpliceCore® platform’s efficacy in Triple Negative Breast Cancer (TNBC).
- Series A Financing (Sept 29, 2021): Raised funds to scale AI-powered RNA splicing drug discovery platform.
- Awards and Grants:
- National Institutes of Health (NIH) SBIR Phase II Grant of $1.5M.
- Multiple SBIR grants from National Cancer Institute (NCI).
Press Coverage:
- Widespread Recognition: Featured in media outlets such as Business Wire, New York Business Journal, and Innovate Long Island for its innovative AI applications in drug discovery.
- Awards:
- Named North American Winner of Innovate AI Competition (May 1, 2018).
- $2.35M seed round closure launching SpliceCore™ Platform (Nov 28, 2017).
Conclusion
Contact Information:
- General: info@envisagenics.com
- Partnership: partner@envisagenics.com
- Careers: careers@envisagenics.com
_Last updated: 2024_
This report encapsulates key information about Envisagenics, focusing on its mission, innovative products, and recent collaborative advancements.